Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
Support Statement: This activity is supported by educational grants from Eisai, Inc.; Novo Nordisk; Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc.
Target Audience: The intended audience for this activity is family physicians and other health care professionals involved in the treatment of patients with obesity.
Learning Objectives:
Upon successful completion of this educational activity, participants should be better able to:
- Evaluate interventions that assist clinicians in their ability to identify patients with obesity, promote weight loss, and manage obesity-related comorbidities.
- Apply clinical data supporting the role and real world use of pharmacologic therapy in the practice setting for patients with obesity.
- Individualize care for patients with overweight and obesity by applying practice tools that assist in acquiring a comfort level with the use of medication to treat these patients.
Activity Chair
John J. Russell, MD
Clinical Associate Professor of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA
Associate Director, Family Medicine Residency Program
Abington Memorial Hospital
Abington, PA
Faculty
Scott Kahan, MD, MPH
Johns Hopkins Bloomberg School of Public Health
Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity Alliance
Director, National Center for Weight & Wellness
Washington, DC
Donna H. Ryan, MD, FACP
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Christopher D. Still, DO, FACN, FACP
Medical Director
Center for Weight Management
Director, Geisinger Obesity Institute
Associate, Department of Gastroenterology & Nutrition
Geisinger Health Care System
Danville, PA
External Reviewer:
Ronald Codario, Jr., MD
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 15, 2014, to December 14, 2015.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, view the CME Content, complete the CME posttest, and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty members report the following relationship:
John J. Russell, MD
Speakers Bureau: Sanofi Pasteur
Advisory Committee: Takeda Pharmaceuticals, Valeant
Scott Kahan, MD, MPH
Consulting Fee: Novo Nordisk
Speakers Bureau: Eisai, Novo Nordisk, Takeda Pharmaceuticals, Vivus, Inc.
Scientific Advisory Board: Eisai, Takeda Pharmaceuticals, Vivus, Inc.
Book Royalties: Johns Hopkins University Press, Lippincott, Williams & Wilkins, Wolters Kluwer
Donna H. Ryan, MD, FACP
Consulting Fee: Eisai, Novo Nordisk, Takeda Pharmaceuticals, Vivus, Inc.
Speakers Bureau: Eisai, Takeda Pharmaceuticals, Vivus, Inc.
Ownership Interest: Scientific Intake
Christopher D. Still, DO, FACN, FACP
Consulting Fee: Eisai, Takeda Pharmaceuticals, Vivus, Inc.
Speakers Bureau: Eisai, Takeda Pharmaceuticals, Vivus, Inc.
External reviewer reports the following relationship(s):
Ronald Codario, Jr., MD
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyrights
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2014 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicomeded.com.